Genmab — August 2014
-
nej eksempelvis DUobody aftalen med Lilly kan jo nok tænkes at være udenfor cancer
-
Fra Solsens link: The suitability of the DuoBody platform for bispecific discovery approaches, showing the importance of doing this in the final format - illustrated by surprising findings, will be shown in a case study selecting a lead cMetxEGFR bispecific antibody.
-
Fra Solsens link 2: We show how specific IgG point mutants promote Fc:Fc interactions and stimulate effector functions only after antigen binding, while maintaining their monomeric state in solution. This insight has been developed into our Hexabody technology.
-
den kræver tålmodighed. Den tager aldrig ryk opad når det syntes åbenlyst. Det er altid lidt når man mindst venter det den pludselig stiger 15-20%
-
-
19% ? mener jan har sagt 40?
-
Klart der bruges mindre. Patienterne dropper jo ud undervejs fordi de bliver forgiftet
-
SEB har en god indkøbsalgoritme igang
-
og de har endda omkring 210 i kursmål så vidt jeg ved, men måske de har opjusteret
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind